Study at a glance
How do cells make active vitamin D?
Cells first need access to 25-hydroxyvitamin D, the main form measured in a vitamin D blood test. An enzyme, a protein that carries out a chemical reaction, can convert it into calcitriol, the active hormone. The kidneys supply much of the hormone in blood, while some other tissues make it for local use.
Do all tissues process vitamin D in the same way?
No. Tissues differ in how they take in forms of vitamin D and control how these forms are changed. The same basic pathway can therefore produce different responses in different cells.
How is the vitamin D signal brought under control?
Enzymes break down forms of vitamin D through several steps. Active vitamin D can also increase the machinery involved in its own breakdown. This helps control how long a signal lasts, although some breakdown products still have effects.
Read the full article below ↓The cellular vitamin D pathway can be followed from metabolite access to activation, signalling and clearance, but it should not be mistaken for a rigid assembly line. Each stage can be regulated differently by tissue, so the useful question is how the stages connect while preserving those differences.
1. Cellular metabolism starts with access to substrate
Most circulating 25(OH)D is carried by vitamin D-binding protein. Renal proximal tubular cells can recover DBP-bound metabolite through megalin/cubilin-mediated endocytosis, while many other cells rely more heavily on free or bioavailable 25(OH)D. Before an enzyme can act, the cell must therefore solve a tissue-specific substrate-access problem.
This is the first connection in the pathway: transport biology determines what can become available for intracellular metabolism.
2. Available 25(OH)D can be activated locally
Once 25(OH)D is accessible inside a cell, CYP27B1 can convert it to 1,25(OH)2D. In kidney this reaction contributes importantly to circulating hormone and is governed by systemic mineral feedback. In extrarenal tissues, the same reaction can support local autocrine or paracrine signalling under different regulatory inputs.
This is where cellular uptake connects to Vitamin D Intracrine Activity and to the wider Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1): substrate delivery and enzyme regulation jointly determine local active-ligand formation.
3. VDR signalling feeds information back into metabolism
Locally produced or circulating 1,25(OH)2D can bind VDR and alter transcription. Among the important metabolic consequences is induction of CYP24A1 in many target cells. Rising active ligand can therefore increase the capacity that later metabolises both active hormone and precursor.
The pathway is consequently not a one-way sequence from precursor to response. Signalling changes the metabolic environment that shapes subsequent exposure.
4. Clearance is multistep and varies by tissue
CYP24A1 can direct vitamin D metabolites through C24 and C23 oxidation pathways, while CYP3A4 provides an additional route in liver and intestine. The approximately ten-fold extension of 1,25(OH)2D plasma half-life in Cyp24a1-null mice shows the scale of CYP24A1’s clearance role, but some downstream products retain biological activity.
Vitamin D Clearance and Degradation therefore describes progressive, product-specific turnover rather than a single instantaneous off switch.
The pathway is a regulated balance, not a rigid assembly line
Putting the stages together gives a more useful model: uptake determines substrate access; CYP27B1 can create active ligand; VDR signalling changes cellular transcription; CYP24A1 and other enzymes constrain persistence and route metabolites onward. Tissue-specific regulation changes the relative strength of every stage.
The sequence is real enough to guide the reader from access to activation to clearance, but it is not universal in its details. The accompanying tissue context explains why the same pathway components can produce different local outcomes in kidney, immune cells, epithelia, muscle and other tissues.
Experimental scale helps connect the stages
The sequence becomes clearer when the experiments are read together. Blocking renal megalin-dependent uptake can reduce DBP uptake to a small fraction of control, showing that substrate delivery can be a major constraint before activation begins. In other cell types, the size of that constraint changes with receptor expression and differentiation state.
At the activation stage, human CYP27B1 loss-of-function shows that precursor availability cannot compensate for a severe failure of 1α-hydroxylation. Conversely, dysregulated extrarenal CYP27B1 in inflammatory disease shows that local conversion can become large enough to influence the systemic circulation when normal tissue-specific restraint is lost.
At the clearance stage, removing CYP24A1 in mice extends active-hormone half-life from roughly 6 to 60 hours. That result gives scale to the termination arm: the cell does not merely create active ligand and then passively wait for it to disappear. Metabolic removal is an active determinant of how long the signal persists.
Read as a sequence, Vitamin D Metabolism at the Cellular Level has several control points: access can constrain activation, activation can be locally regulated, and catabolism can shorten or redirect exposure.
The tissue context explains why the strength and regulation of those control points differ between cell types.
Related reading
SNP rs11185644 in RXRA gene and SNP rs2235544 in DIO1 gene predict dosage requirements in a cross-sectional sample of hypothyroid patients
This study aimed to study the influence of genetic polymorphisms on levothyroxine replacement requirements.
Original paper ↗Read more →Urinary Vitamin D Binding Protein: A Potential Novel Marker of Renal Interstitial Inflammation and Fibrosis
We investigated the value of urinary vitamin D binding protein excretion (uVDBP) as a tubulointerstitial inflammation and fibrosis marker in adriamycin rats, and tested whether uVDBP parallels renal damage and responds to therapy intensification in humans.
Original paper ↗Read more →Urinary Vitamin D Binding Protein and Kidney Injury Molecule-1 Are Potent Predictors of Acute Kidney Injury After Left Ventricular Assist Device Implantation
This study aimed to predict AKI within 90 days post-LVAD by evaluating urinary levels of vitamin D binding protein (VDBP) and kidney injury molecule-1 (KIM-1).
Original paper ↗Read more →Urinary Vitamin D Binding Protein and KIM-1 Are Potent New Biomarkers of Major Adverse Renal Events in Patients Undergoing Coronary Angiography
The purpose of our study was to explore the potential role of urinary VDBP as a biomarker of an acute renal damage.
Original paper ↗Read more →Vitamin D Binding Protein Is Not Involved in Vitamin D Deficiency in Patients with Chronic Kidney Disease
Objective.
Original paper ↗Read more →Vitamin D Receptor and Vitamin D Binding Protein Gene Polymorphisms Are Associated with Renal Allograft Outcome
Vitamin D deficiency has adverse effects on renal allograft outcomes, and polymorphisms of genes encoding vitamin D-binding protein (VDBP) and vitamin D receptor (VDR) are defined to play a role in these conditions.
Original paper ↗Read more →Cellular uptake and intracellular handling of vitamin D metabolites: Full Evidence Review
full evidence review of cellular vitamin D metabolite uptake, intracellular handling, megalin-mediated transport and differences between tissues.
Read more →Modulation of renal inflammation and tubular injury by calcitriol in patients with early diabetic kidney disease: a randomized controlled trial
This double-blind, randomized controlled trial investigated the effects of calcitriol supplementation on kidney injury biomarkers in patients with early DKD.
Original paper ↗Read more →25-Hydroxyvitamin D and Vitamin D Binding Protein Levels in Patients With Primary Hyperparathyroidism Before and After Parathyroidectomy
To evaluate vitamin D binding protein and free 25-hydroxyvitamin D [25(OH)D] levels in healthy controls compared to primary hyperparathyroidism (PHPT) patients, and to examine PHPT before and after surgery.
Original paper ↗Read more →Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D3 or D2 supplementation
We aimed to investigate the changes of total 25(OH)D, 25(OH)D3 and 25(OH)D2 in a Thai cohort, according to type of vitamin D supplement (vitamin D3 or D2) and DBP genotype, after receiving vitamin D3 or D2 for 3 months.
Original paper ↗Read more →Genetic associations with 25-hydroxyvitamin D deficiency in HIV-1-infected youth: fine-mapping for the GC/DBP gene that encodes the vitamin D-binding protein
Serum 25-hydroxyvitamin D [25(OH)D] is often deficient (.
Original paper ↗Read more →Genetic variant in vitamin D-binding protein is associated with metabolic syndrome and lower 25-hydroxyvitamin D levels in polycystic ovary syndrome: A cross-sectional study
All participants were genotyped for polymorphisms rs2282679, rs4588, and rs7041.
Original paper ↗Read more →Maternal and Neonatal Vitamin D Binding Protein Polymorphisms and 25-Hydroxyvitamin D Cutoffs as Determinants of Neonatal Birth Anthropometry
Our aim was to assess the combined effect of maternal and neonatal VDBP polymorphism heterogeneity in conjunction with different maternal and neonatal 25(OH)D cutoffs on the neonatal anthropometric profile at birth.
Original paper ↗Read more →The GC2 haplotype of the vitamin D binding protein is a risk factor for a low plasma 25-hydroxyvitamin D concentration in a Han Chinese population
Compared with VDI, VDS, or both, VDD showed higher plasma concentrations of fasting blood glucose, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides in males (P 0.05).
Original paper ↗Read more →The Role of Vitamin D Binding Protein, Total and Free 25-Hydroxyvitamin D in Diabetes
Vitamin D is important for bone health, but may also have extra-skeletal effects.
Original paper ↗Read more →Vitamin D-Binding Protein, Bioavailable, and Free 25(OH)D, and Mortality: A Systematic Review and Meta-Analysis
Introduction: Observational studies reported inverse associations between serum total 25-hydroxyvitamin D (25(OH)D) concentrations and mortality.
Original paper ↗Read more →Vitamin D Binding Protein Genotype Is Associated with Serum 25-Hydroxyvitamin D and PTH Concentrations, as Well as Bone Health in Children and Adolescents in Finland
We examined the role of GC genotypes in S-25(OH)D status and BMD in 231 Finnish children and adolescents aged 7−19 yr.
Original paper ↗Read more →Vitamin D Binding Protein Impact on 25-Hydroxyvitamin D Levels under Different Physiologic and Pathologic Conditions
The aim of this review is to assess DBP concentration in different physiological and pathophysiological conditions.
Original paper ↗Read more →Vitamin D-Binding Protein Polymorphisms, 25-Hydroxyvitamin D, Sunshine and Multiple Sclerosis
Blacks have different dominant polymorphisms in the vitamin D-binding protein (DBP) gene that result in higher bioavailable vitamin D than whites.
Original paper ↗Read more →Vitamin D Binding Protein Explained
A physiology-first explanation of vitamin D binding protein, detailing how it buffers circulation, regulates delivery, and shapes cellular and system-level vitamin D availability.
Read more →Circulating 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Concentrations and Postoperative Infections in Cardiac Surgical Patients: The CALCITOP-Study
In 3,340 consecutive cardiac surgical patients, we investigated the association of circulating 25-hydroxyvitamin D (25OHD; indicator of nutritional vitamin D status) and 1,25-dihydroxyvitamin D (1,25[OH]2D; active vitamin D hormone) with nosocomicial infections.
Original paper ↗Read more →